KetoMed: Product Information

KETOMED- ketoprofen injection, solution
Bimeda, Inc.


Sterile Solution, 100 mg/mL

For intravenous use in horses only.


Federal law restricts this drug to use by or on the order of a licensed veterinarian.


Ketoprofen is a non-steroidal anti-inflammatory agent of the propionic acid class that includes ibuprofen, naproxen, and fenoprofen. Each mL of KetoMed (ketoprofen) contains 100 mg of ketoprofen in an aqueous formulation containing: L-Arginine, 70 mg; citric acid (to adjust pH); benzyl alcohol, 0.025 g (as preservative).
It is packaged in a multiple dose bottle.


KetoMed is a non-narcotic, non-steroidal anti-inflammatory agent with analgesic and antipyretic properties.
In horses, intravenous dosages of ketoprofen ranging from 0.5 to 1.5 mg/lb resulted in dosage dependent anti-inflammatory effects in the chronic adjuvant carpitis model as depicted in the following graph.


(intravenous ketoprofen, mean ± sem, n = 4) *

image description
(click image for full-size original)

*sem = standard error of the mean

n = number of animals

Additional studies using the same model in horses have shown that the effects of ketoprofen are maximal by 12 hours and still measurable at 24 hours after each dosage as depicted in the following graph.


(mean ± sem, n = 6) *

image description
(click image for full-size original)

*sem = standard error of the mean

n = number of animals


Horses were found to tolerate ketoprofen given intravenously at dosages of 0, 1, 3 and 5 mg/lb once daily for 15 consecutive days (up to five times the recommended dosage for three times the usual duration) with no evidence of toxic effects. In clinical studies, intravenous injection of 1 mg/lb/day for five days resulted in no injection site irritation or other side effects.

At 15-fold overdose (15 mg/lb/day) for five days one of two horses developed severe laminitis, but no gross lesions or histologic changes were observed. The toxic effects observed in the horses given a 25-fold overdose (25 mg/lb/day) for five days included inappetence, depression, icterus, abdominal swelling and postmortem findings of gastritis, nephritis and hepatitis.


KetoMed (ketoprofen) is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse.


The recommended dosage is 1 mg/lb (1 mL/100 lbs) of body weight once daily. Treatment is administered by intravenous injection and may be repeated for up to five days. Onset of activity is within two hours with peak response by 12 hours.


There are no known contraindications to this drug when used as directed. Intra-arterial injection should be avoided. Do not use in a horse if it has previously shown hypersensitivity to ketoprofen.


This product should not be used in breeding animals since the effects of KetoMed on fertility, pregnancy or fetal health in horses have not been determined.


Studies to determine activity of KetoMed when administered concomitantly with other drugs have not been conducted. Drug compatibility should be monitored closely in patients requiring
adjunctive therapy.


Do not use in horses intended for human consumption.


During investigational studies, no significant side effects were reported.

To report suspected adverse drug events, for technical assistance, or to obtain a copy of the Safety Data Sheet (SDS), contact Bimeda, Inc. at 1-888-524-6332. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at


KetoMed (ketoprofen) Solution 100 mg/mL is available in 50 mL and 100 mL multidose bottles.

Store at 20°C — 25°C (68°F- 77°F); excursions permitted between 15°C — 30°C (59°F — 86°F). Do not freeze.

Use within 28 days of first puncture.

Approved by FDA under ANADA # 200-625
Manufactured for:
Bimeda, Inc.

Le Sueur, MN 56058


image description
(click image for full-size original)

image description
(click image for full-size original)
image description
(click image for full-size original)
ketoprofen injection, solution
Product Information
Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC:61133-4007
Route of Administration INTRAVENOUS DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Inactive Ingredients
Ingredient Name Strength
ARGININE 70 mg in 1 mL
# Item Code Package Description Multilevel Packaging
1 NDC:61133-4007-1 50 mL in 1 BOTTLE None
2 NDC:61133-4007-2 100 mL in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANADA ANADA200625 02/08/2021
Labeler — Bimeda, Inc. (060492923)
Name Address ID/FEI Operations
Bimeda- MTC 256232216 manufacture
Name Address ID/FEI Operations
EUROAPI Germany GmbH 343459891 api manufacture

Revised: 01/2022 Bimeda, Inc. provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by Every individual animal healthcare product label entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.

Our database mirrors the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. provides the full animal health subset of the FDA's repository. Veterinary information provided here is not intended as a substitute for direct consultation with a qualified veterinary professional.

Terms of Use | Copyright © 2022. All Rights Reserved.